Why Did Agios Pharmaceuticals Stock Plunge 10.54% Ahead of Earnings?

On April 10, 2025, Agios Pharmaceuticals' stock experienced a significant drop of 10.54% in pre-market trading, reflecting a challenging period for the biopharmaceutical company.

Agios Pharmaceuticals is scheduled to release its earnings report on May 1, 2025. The company's stock has been ranked as a sell candidate, indicating a bearish outlook among investors. This ranking is supported by the recent downward revision of the Zacks Consensus Estimate for its current year earnings by 18.9% over the last 60 days.

Analysts have also lowered the price target for Agios Pharmaceuticals to $74 from $75 at Scotiabank, further contributing to the negative sentiment surrounding the stock. The company's 52-week low of $24.33 highlights the turbulent market conditions it is currently navigating.

Despite these challenges, Agios Pharmaceuticals continues to focus on the development of treatments for rare genetic metabolic disorders, a critical area of its business. The company's market performance will be closely watched as it approaches its earnings release date.